This post was originally published on this site
Initiating one of the largest coronary drug-eluting balloon registries driving evidence-based practice
MIAMI LAKES, Fla., May 19, 2025 /PRNewswire/ — Cordis, a global leader in interventional cardiovascular technologies, today announced the initiation of the SELUTION Global Coronary Registry. The prospective study will enroll up to 10,000 patients worldwide and will be one of the largest coronary drug-eluting balloon registries to date. The registry will track real-world outcomes of SELUTION SLR™ Drug-Eluting Balloon (DEB) for up to five years and will complement the results from the on-going randomized trials.
Expanding Evidence, Enhancing Clinical Impact
SELUTION SLR™ DEB has demonstrated consistent evidence of effectiveness from pre-clinical studies showing sustained Sirolimus in tissue through 90 days, to proof-of-concept clinical evaluation demonstrating favorable late lumen loss measurements. The SELUTION Global Coronary Registry builds upon the five ongoing Level-1 randomized trials and the recently reported positive peripheral experience which showed extremely competitive and durable results, underscoring Cordis’ dedication to developing meaningful clinical evidence to change the standard of care.
“Drug-eluting balloons are one of the most interesting and exciting new technologies in the coronary interventional space,” said Dr. Ajay J. Kirtane, Professor of Medicine at Columbia University Irving Medical Center and Director of the Columbia Interventional Cardiovascular Care Program. “The creation and initiation of this large real-world registry examining DEB utilization and the practice of PCI with this technology is a welcome development, which will help clinicians better understand where SELUTION SLR™ DEB can deliver the greatest benefits and improved outcomes in their practice.”
Cordis Welcomes Distinguished Clinical Experts to Global Steering Committee
Cordis proudly welcomes a group of internationally recognized interventional cardiologists onto the SELUTION Global Coronary Registry steering committee. These esteemed clinical leaders bring deep expertise and a shared commitment to advancing patient-centered cardiovascular care:
- Dr. Ajay Kirtane (Chairman of the Steering Committee), Columbia University Irving Medical Center, USA
- Professor Alexandre Abizaid, MD, PhD, Director of Interventional Cardiology, Incor – Universidade de Sao Paulo, Brazil
- Professor Robert Byrne, Director of Cardiology and Cardiovascular Research Institute (CVRI) Dublin, Mater Private Network; School of Pharmacy and Biomolecular Sciences, RCSI University, Ireland
- Dr. Nieves Gonzalo, Interventional Cardiologist, Hospital Clinico San Carlos, Spain
- Dr. Robert Yeh, Director of Richard A. and Susan F. Smith Center for Outcomes Research, Section Chief, Interventional Cardiology, Beth Israel Deaconess Medical Center, USA
“The history of Cordis is grounded in a commitment to clinical evidence; putting patients first means backing our technology with the strongest evidence we can provide. The launch of the SELUTION Global Coronary Registry reaffirms this commitment. We look forward to sharing groundbreaking coronary results this Fall,” said Dr. George Adams, Chief Medical Officer at Cordis.
About SELUTION SLR™ DEB
Commercially available in more than 40 countries, SELUTION SLR™ DEB ushers in the next generation of drug-eluting balloon technology. It is designed to deliver sustained, predictable Sirolimus release without leaving a permanent implant, allowing physicians to “Go Beyond Metal” while preserving future treatment options.
About Cordis
Cordis is a global leader in the development and manufacturing of interventional cardiovascular and endovascular technologies. For over 60 years, we have been committed to improving patient lives through innovation, enhanced clinical outcomes, education, and service. Our mission is to be the heart of innovation to transform cardiovascular care.
For more information about Cordis, please visit Cordis.com and follow Cordis on LinkedIn.
Media Contact:
Kelly May
Director of Corporate Communications
[email protected]
SOURCE Cordis
